Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
19 janv. 2021 08h30 HE | Vallon Pharmaceuticals Inc.
ADAIR demonstrated bioequivalence to immediate release (IR) d-AMPH when administered orally and appears to be less desirable to recreational drug abusers when snorted compared to currently available...
RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.
04 mars 2020 09h00 HE | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety...
logo long.jpg
Global CNS Specific Antisense Oligonucleotide Market to Surpass US$ 6.8 Billion by 2026 – Coherent Market Insights
08 févr. 2019 08h30 HE | CMI
SEATTLE, Feb. 08, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CNS specific antisense oligonucleotide market is valued at US$ 883.7 million in 2017, and is projected to...
RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data:
25 juil. 2018 09h00 HE | RespireRX Pharmaceuticals Inc.
Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain Glen Rock, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI)...
Advinus Therapeutics and P2D Bioscience Enter Into a Research and Development Collaboration for Attention Deficit Hyperactivity Disorder (ADHD)
24 juil. 2012 08h35 HE | P2D Bioscience
CINCINNATI, OH and BANGALORE, INDIA--(Marketwire - Jul 24, 2012) -  Advinus Therapeutics Ltd., a drug discovery and development company, and P2D Bioscience, a CNS-focused specialty...